• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Roche denies rumors it will shop diabetes unit, earnings

February 1, 2017 By Sarah Faulkner

RocheRoche denies rumors it will shop diabetes unit, earnings (PINK:RHHBY) denied rumors that it was considering selling its diabetes unit today, saying that it is “committed” to the business. The company also predicted that competition and spending on new drugs would stall its margin growth in 2017, as patents expire for its blockbuster medications.

The Swiss drugmaker’s 3 top-selling cancer drugs, Rituxan, Herceptin and Avastin, bring in annual revenue of more than 20 billion Swiss francs, Reuters reported, and they face incoming competition from biosimilar copies. The 1st copies of Rituxan and Herceptin could hit the European market later this year, the news outlet said.

CEO Severin Schwan said he dialed back 2017 profit growth expectations because he plans to invest in new products, such as its cancer immunotherapy Tecentriq and Cotellic for skin cancer.

“We’re going through a transition of our portfolio but the good news is, we can overcompensate with the launch of new medicines,” Schwan explained.

“Biosimilars will hit Roche in the current year in Europe and then in 2018 in America in a big way, putting Roche under pressure to keep up new pipeline news and successful drug launches,” Michael Nawrath, a Zuercher Kantonalbank analyst, wrote in a note to investors.

Net income climbed to 12.7 billion francs in 2016, missing the 12.8 billion franc estimate from analysts. Earnings per share are pegged to grow in line with a low- to mid-single digit sales rise, the company reported.

Schwan responded to President Donald Trump’s call to drugmakers to lower prices and invest more in the U.S., saying that Roche has an established U.S. presence in its Genentech unit. The CEO also argued that innovative companies would likely still be rewarded under any new system.

He expects Roche’s new multiple sclerosis medicine, Ocrevus, to win FDA approval in March after it was delayed last December, according to Reuters.

In early December last year, Senseonics (NYSE:SENS) expanded its exclusive distribution agreement with Roche for its implantable continuous glucose monitoring system for people with diabetes.

The new agreement includes all of Europe, the Middle East and Africa, excluding Scandinavia, Finland and Israel.

Filed Under: Diabetes, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Roche, Senseonics

IN CASE YOU MISSED IT

  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor
  • Medtronic to separate Diabetes business unit

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS